Biomaterial Database

Transplant outcome of desensitized recipients after donor-specific transfusion. 1987

H Okazaki, and H Takahashi, and S Oguma, and M Jimbo, and M Ishizaki

Department of Surgery, Sendai Shakaihoken Hospital, Japan.

UI	MeSH Term	Description	Entries
D007165	Immunosuppression Therapy	Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs.	Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D008297	Male		Males
D010956	Plasmapheresis	Procedure whereby plasma is separated and extracted from anticoagulated whole blood and the red cells retransfused to the donor. Plasmapheresis is also employed for therapeutic use.	Double Filtration Plasmapheresis,Therapeutic Immunoadsorption,Therapeutic Plasma Adsorption,Therapeutic Plasmapheresis,Adsorption, Therapeutic Plasma,Adsorptions, Therapeutic Plasma,Double Filtration Plasmaphereses,Filtration Plasmapheresis, Double,Immunoadsorption, Therapeutic,Plasma Adsorption, Therapeutic,Plasmaphereses,Plasmapheresis, Double Filtration,Plasmapheresis, Therapeutic,Therapeutic Immunoadsorptions,Therapeutic Plasma Adsorptions,Therapeutic Plasmaphereses
D011379	Prognosis	A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.	Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D001803	Blood Transfusion	The introduction of whole blood or blood component directly into the blood stream. (Dorland, 27th ed)	Blood Transfusions,Transfusion, Blood,Transfusions, Blood
D002648	Child	A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL.	Children
D003888	Desensitization, Immunologic	Immunosuppression by the administration of increasing doses of antigen. Though the exact mechanism is not clear, the therapy results in an increase in serum levels of allergen-specific IMMUNOGLOBULIN G, suppression of specific IgE, and an increase in suppressor T-cell activity.	Allergen Immunotherapy,Allergy Shots,Hyposensitization Therapy,Immunotherapy, Allergen,Venom Immunotherapy,Immunologic Desensitization,Therapy, Hyposensitization,Allergen Immunotherapies,Allergy Shot,Desensitizations, Immunologic,Hyposensitization Therapies,Immunologic Desensitizations,Immunotherapy, Venom,Shot, Allergy,Venom Immunotherapies
D005260	Female		Females
D006084	Graft Rejection	An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient.	Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

H Okazaki, and H Takahashi, and S Oguma, and M Jimbo, and M Ishizaki

Long-term follow-up of living donor renal transplant recipients sensitized after donor specific blood transfusion.

January 2001, Transplantation proceedings,

H Okazaki, and H Takahashi, and S Oguma, and M Jimbo, and M Ishizaki

Deliberate transfusion of potential renal transplant recipients with specific donor blood.

September 1981, American journal of kidney diseases : the official journal of the National Kidney Foundation,

H Okazaki, and H Takahashi, and S Oguma, and M Jimbo, and M Ishizaki

Hepatitis in renal transplant recipients with and without donor-specific blood transfusion.

February 1989, Transplantation proceedings,

H Okazaki, and H Takahashi, and S Oguma, and M Jimbo, and M Ishizaki

Early and Sustained Reduction in Donor-Specific Antibodies in Desensitized Living Donor Kidney Transplant Recipients: A 3-Year Prospective Study.

February 2016, Transplantation direct,

H Okazaki, and H Takahashi, and S Oguma, and M Jimbo, and M Ishizaki

Donor-specific alloantibody upregulation after influenza vaccination in transplant recipients.

November 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,

H Okazaki, and H Takahashi, and S Oguma, and M Jimbo, and M Ishizaki

Donor-Specific Antibodies in Kidney Transplant Recipients.

January 2018, Clinical journal of the American Society of Nephrology : CJASN,

H Okazaki, and H Takahashi, and S Oguma, and M Jimbo, and M Ishizaki

Donor antigen-specific regulatory T-cell function affects outcome in kidney transplant recipients.

May 2011, Kidney international,

H Okazaki, and H Takahashi, and S Oguma, and M Jimbo, and M Ishizaki

Immunologic low-responder in ABO-incompatible renal transplant recipients explored by donor-specific platelet transfusion.

August 1998, Transplantation proceedings,

H Okazaki, and H Takahashi, and S Oguma, and M Jimbo, and M Ishizaki

Donor-specific transfusion and renal allograft outcome.

September 2002, Nephron,